Your browser doesn't support javascript.
loading
Ectopic expression of Klotho in fibroblast growth factor 23 (FGF23)-producing tumors that cause tumor-induced rickets/osteomalacia (TIO).
Kinoshita, Yuka; Takashi, Yuichi; Ito, Nobuaki; Ikegawa, Shiro; Mano, Hiroyuki; Ushiku, Tetsuo; Fukayama, Masashi; Nangaku, Masaomi; Fukumoto, Seiji.
Affiliation
  • Kinoshita Y; Division of Nephrology and Endocrinology, Department of Medicine, The University of Tokyo Hospital, Tokyo 113-8655, Japan.
  • Takashi Y; Diabetes Therapeutics and Research Center, Institute of Advanced Medical Sciences, Tokushima University, Tokushima 770-8503, Japan.
  • Ito N; Division of Nephrology and Endocrinology, Department of Medicine, The University of Tokyo Hospital, Tokyo 113-8655, Japan.
  • Ikegawa S; Laboratory for Bone and Joint Diseases, RIKEN Center for Integrative Medical Sciences, Tokyo 108-8639, Japan.
  • Mano H; National Cancer Center Research Institute, Tokyo 104-0045, Japan.
  • Ushiku T; Department of Pathology and Diagnostic Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo 113-8655, Japan.
  • Fukayama M; Department of Pathology and Diagnostic Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo 113-8655, Japan.
  • Nangaku M; Division of Nephrology and Endocrinology, Department of Medicine, The University of Tokyo Hospital, Tokyo 113-8655, Japan.
  • Fukumoto S; Fujii Memorial Institute of Medical Sciences, Tokushima University, Tokushima 770-8503, Japan.
Bone Rep ; 10: 100192, 2019 Jun.
Article in En | MEDLINE | ID: mdl-30627598
Tumor-induced rickets/osteomalacia (TIO) is a rare paraneoplastic syndrome caused by tumors that ectopically express fibroblast growth factor 23 (FGF23). FGF23 is a bone-derived hormone that regulates serum phosphate concentrations. Patients with TIO develop hypophosphatemic rickets/osteomalacia due to FGF23 excess and suffer from symptoms such as leg deformities, bone pain, skeletal muscle myopathy, and multiple fractures/pseudofractures. Usually, successful surgical removal of the causative tumors normalizes serum FGF23 and phosphate concentrations in patients with TIO. Most FGF23-producing tumors associated with TIO are histologically called phosphaturic mesenchymal tumor, mixed connective tissue variant (PMTMCT). The precise mechanism by which these tumors ectopically overproduce FGF23 outside of bone is yet to be clarified. Therefore, we performed an RNA sequencing analysis of a PMTMCT that was found in the left parotid gland of a patient with TIO. Among the upregulated genes, we focused on Klotho, the protein product of which is a single pass transmembrane protein that works along with an FGF receptor 1c as a receptor complex for FGF23. Subsequent histological analysis confirmed the ectopic expression of Klotho in other PMTMCTs. From these results, we assume that the ectopic expression of Klotho in PTMMCTs enables a positive feedback loop in FGF23 production via the activation of FGF receptor 1c and exacerbates disease manifestations in TIO.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Bone Rep Year: 2019 Document type: Article Affiliation country: Japan Country of publication: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Bone Rep Year: 2019 Document type: Article Affiliation country: Japan Country of publication: United States